Open in interactive viewer → charts, metric popovers & call review

Ionis Halved Its Launch Guide and Moved Breakeven to 2029 — The Pipeline That Justified $86 Is Gone

TRYNGOLZA's first full quarter in sHTG produced $9 million and a guidance cut to ~$50 million; the two Phase III failures now cost a year of cash-flow timing.
IONS · Earnings Call · 2026-11-09

The Number That Moved

In July, Ionis told investors to expect $100–110 million of TRYNGOLZA revenue in 2026. On this call the company halved it. “For TRYNGOLZA, we are lowering our 2026 full year revenue guidance to approximately $50 million to reflect a more gradual launch ramp than we had anticipated.” — Brett Monia, Chief Executive Officer · 2026-11-09 That is not a rounding error — it is the first commercial year of the asset that underpins the entire equity story, the one management still frames as a multibillion-dollar peak sales opportunity of $3 billion-plus in the U.S. The rest of the quarter is a study in contrast. DAWNZERA did exactly what it was supposed to do: $37 million in Q3, up roughly 40% sequentially, $79 million year-to-date, with the $110–120 million full-year guide held. ZANVASTRO, the first FDA-approved disease-modifying therapy for Alexander disease, booked its first product revenue and the first patients received commercial treatment. Total revenue of $243 million in the quarter and $757 million year-to-date was up 55% and 64% respectively ex the prior-year sapablursen payment. And yet the stock sits roughly 63% below where it traded in early July, with the $2.8 billion effective net cash pile now the main thing standing between the company and a financing decision it would rather not make.

Enthusiasm Was Never the Constraint

The company's own keyword set tells the story of the pivot. Last quarter the language was anticipation; this quarter it is execution mechanics: prescriber base, depth of prescribing, repeat prescribers. Roughly 1,500 prescribers wrote TRYNGOLZA through September, only about 24% wrote more than one script, and 33% of commercial lives had coverage policies in place. Management now talks about translating HCP enthusiasm into action — a phrase that implicitly concedes enthusiasm was not the binding constraint. The prior calls are the awkward comparison. In July, five weeks in: “Internally, we are absolutely meeting the expectations of the launch here, keeping in mind that we're only 4 or 5 weeks into this, so it's very early.” — Kyle Jenne, Head of Commercial or Commercial Executive · 2026-07-29 One quarter later the full-year number is cut in half and the culprit is a slower-than-expected launch ramp. Brett Monia's defense is that the demand signal is intact even if the revenue is not: “Demand is increasing for TRYNGOLZA. And we're also very pleased with the persistency that TRYNGOLZA is demonstrating.” — Brett Monia, Chief Executive Officer · 2026-11-09

It's really important to remember that we are 3 months into — these numbers represent 3 months into a launch, delivering a medicine that is providing benefit to patients that physicians have never had experience with before.

Brett Monia, Chief Executive Officer · 2026-11-09
Fair as far as it goes — and it is the argument that was equally available in July, when the guide was still $100 million. Note also that in April, before the June approval, the commercial chief was already setting expectations low: “The trajectory, I think, is going to be modest at the beginning here in 2026.” — Kyle Jenne, President, Commercial Operations · 2026-04-29 The defensible read is that Ionis is building a genuinely new market — a new treatment paradigm in severe hypertriglyceridemia, where acute pancreatitis risk reduction is the selling point and cardiologists, endocrinologists and lipidologists have to be taught which patient to put on a monthly auto-injector. The less generous read is that a company with three launches in flight briefly mistook physician intent for a demand curve.

What Stopped Being Said

The most revealing thing about this transcript is what is missing from it. Last quarter's keyword list was led by CARDIO TTRansform, with HORIZON, pelacarsen, monotherapy and combination-use language filling a large share of the top thirty. This quarter, those two Phase III disappointments get one framing sentence in the prepared remarks — “Although 2 recent Phase III readouts did not deliver the outcomes we hoped for, we have achieved a number of other important firsts.” — Brett Monia, Chief Executive Officer · 2026-11-09 — and thereafter appear only when an analyst asks directly. The silence is the signal. Eplontersen in ATTR-CM and pelacarsen in Lp(a) were the pipeline optionality that carried the stock to a February peak; today they are an asterisk. The financial consequence is explicit and, notably, two-cause: “Based on the recent Phase III setbacks and the slower-than-anticipated TRYNGOLZA launch, we do expect the timing to shift from 2028 to 2029.” — Elizabeth L. Hougen, Chief Financial Officer · 2026-11-09 The launch miss alone would not have moved the goalpost, and neither would the trial failures alone. Together they push the positive cash flow milestone — the promise that has justified a reinvestment-heavy model for years — out by a full year.

Quick Start and the Cash Clock

The top-ranked new keyword on this call is Quick Start, the free-drug bridge that lets patients begin treatment while coverage is secured. It is good medicine and rational commercial policy, and it is also why a halved guide is not quite a halved demand picture, as the CFO's outlook makes plain: “Our guidance also takes into account the expansion of our Quick Start program, which helps patients begin treatment while coverage is being secured.” — Elizabeth L. Hougen, Chief Financial Officer · 2026-11-09 Kyle Jenne declined to say what proportion of starts are on free drug, or the expected duration of that bridge. Investors should assume it is material and that it defers revenue rather than destroying it. Against that, the balance sheet deserves attention. Quarterly revenue of $246 million is a record outside the 2019 and 2025 one-time-payment spikes, and price-to-revenue of 11.8x is not a distressed multiple. The company expects to end the year with more than $1.6 billion in cash from $1.9 billion at Q3 — a burn it can fund, but not indefinitely, while three launches ramp and the fourth-quarter cash number is a projection rather than a fact.

What Is Left Standing

Not everything is damaged. Sefaxersen met the primary endpoint in the Phase III IgA nephropathy study with Roche set to handle the filing; ulefnersen hit its FUS-ALS Phase III; HIBSAGO was approved in the U.S. and Japan and triggered a $30 million Q4 milestone; obudanersen reads out in the second half of next year. The partner portfolio threw off $107 million in the quarter, and the marketed portfolio now spans FCS, sHTG, HAE and neurology — a genuinely rare footprint for a company this size. Even the broader market tape has been rewarding exactly this kind of high unmet need biotech story, which is why the shares' collapse is company-specific rather than sector-wide. That is a real pipeline. It is simply no longer the pipeline investors paid for in February. The story of this quarter is not that Ionis is broken — revenue grew 55%, DAWNZERA is compounding, and the cash cushion buys time. The story is that the company spent the first half of the year describing a launch on track, then cut the guide in half and pushed profitability out a year, and now needs physician intent to convert into paid prescriptions faster than it converted enthusiasm into guidance.